vs
Side-by-side financial comparison of PROTHENA CORP PUBLIC LTD CO (PRTA) and Spyre Therapeutics, Inc. (SYRE). Click either name above to swap in a different company.
Over the past eight quarters, PROTHENA CORP PUBLIC LTD CO's revenue compounded faster (-35.2% CAGR vs -100.0%).
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted next-generation therapies for patients with rare, serious autoimmune and inflammatory diseases. It advances pipeline candidates through preclinical and early clinical stages to address unmet medical needs for global patient populations.
PRTA vs SYRE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $0 |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | -99.0% | — |
| Net Profit YoY | 62.7% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0K | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $2.8M | — | ||
| Q4 24 | $2.1M | $0 | ||
| Q3 24 | $970.0K | $0 | ||
| Q2 24 | $132.0M | $0 | ||
| Q1 24 | $50.0K | $0 |
| Q4 25 | — | — | ||
| Q3 25 | $-36.5M | — | ||
| Q2 25 | $-125.8M | — | ||
| Q1 25 | $-60.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-59.0M | $-69.0M | ||
| Q2 24 | $66.9M | $-38.8M | ||
| Q1 24 | $-72.2M | $-43.9M |
| Q4 25 | — | — | ||
| Q3 25 | -1666.3% | — | ||
| Q2 25 | -1914.4% | — | ||
| Q1 25 | -2319.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6857.0% | — | ||
| Q2 24 | 44.2% | — | ||
| Q1 24 | -163056.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | -1513.1% | — | ||
| Q2 25 | -2845.4% | — | ||
| Q1 25 | -2128.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6082.6% | — | ||
| Q2 24 | 50.7% | — | ||
| Q1 24 | -144478.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.68 | — | ||
| Q2 25 | $-2.34 | — | ||
| Q1 25 | $-1.12 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.10 | $1.06 | ||
| Q2 24 | $1.22 | $0.59 | ||
| Q1 24 | $-1.34 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.5M | $89.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $280.5M | $517.8M |
| Total Assets | $326.8M | $608.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $307.5M | — | ||
| Q3 25 | $330.8M | — | ||
| Q2 25 | $371.4M | — | ||
| Q1 25 | $417.9M | — | ||
| Q4 24 | $471.4M | $89.4M | ||
| Q3 24 | $519.3M | $71.6M | ||
| Q2 24 | $564.1M | $45.1M | ||
| Q1 24 | $546.5M | $227.6M |
| Q4 25 | $280.5M | — | ||
| Q3 25 | $295.0M | — | ||
| Q2 25 | $324.3M | — | ||
| Q1 25 | $437.7M | — | ||
| Q4 24 | $486.9M | $517.8M | ||
| Q3 24 | $534.4M | $327.4M | ||
| Q2 24 | $581.9M | $374.4M | ||
| Q1 24 | $502.4M | $152.3M |
| Q4 25 | $326.8M | — | ||
| Q3 25 | $352.6M | — | ||
| Q2 25 | $399.1M | — | ||
| Q1 25 | $495.3M | — | ||
| Q4 24 | $547.1M | $608.5M | ||
| Q3 24 | $595.3M | $421.1M | ||
| Q2 24 | $645.6M | $436.1M | ||
| Q1 24 | $623.2M | $487.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-163.6M | $-37.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-163.6M | — | ||
| Q3 25 | $-40.6M | — | ||
| Q2 25 | $-46.3M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $-150.1M | $-37.2M | ||
| Q3 24 | $-45.2M | $-29.4M | ||
| Q2 24 | $16.0M | $-62.2M | ||
| Q1 24 | $-73.1M | $-28.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
